Main Line biotech firm raises $40M in Series A round to advance new high blood pressure treatment
April 06, 2021 at 07:00 AM EDT
The company was founded in 2020.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions. |
|